SARS-CoV-2 Vaccines
AssigneeJanssen Pharmaceuticals, Inc.
InventorsJason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Aneesh VIJAYAN
Life of this patent
Estimating the term…
Abstract
RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.
Claims26
An RNA replicon encoding a recombinant pre-fusion SARS CoV-2 S protein or a fragment thereof, wherein the SARS CoV-2 protein comprises an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:12, SEQ ID NO:14 or a fragment thereof.
An RNA replicon, comprising, ordered from the 5′- to 3′-end,
- (1) a 5′-UTR having the polynucleotide sequence of SEQ ID NO:18,
- (2) a 5′ replication sequence having the polynucleotide sequence of SEQ ID NO:19,
- (3) a DLP motif comprising the polynucleotide sequence of SEQ ID NO:20,
- (4) a polynucleotide sequence encoding a P2A sequence of SEQ ID NO:22,
- (5) a polynucleotide sequence encoding alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 having the nucleic acid sequences of SEQ ID NO:
- 24, SEQ ID NO:
- 25, SEQ ID NO:
- 26 and SEQ ID NO:
- 27, respectively,
- (6) a subgenomic promoter having polynucleotide sequence of SEQ ID NO:
- 16,
- (7) a polynucleotide sequence encoding a pre-fusion SARS CoV-2 S protein having the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 1-4, 12, and 14, or a fragment thereof, and
- (8) a 3′ UTR having the polynucleotide sequence of SEQ ID NO:28.
An RNA replicon comprising the polynucleotide sequence of SEQ ID NO:30 or SEQ ID NO:31.
The method of claim 17, wherein the heterologous prime-boost administration regimen comprises a prime-administration of the vaccine of claim 29 to prime the immune response and a boost-administration of a vaccine comprising an adenoviral vector encoding a recombinant pre-fusion SARS CoV-2S protein or fragment thereof to boost the immune response.
The method of claim 17, wherein the heterologous prime-boost administration regimen comprises a prime-administration of a vaccine comprising an adenoviral vector encoding a recombinant pre-fusion SARS CoV-2S protein or fragment thereof to prime the immune response and a boost-administration of the vaccine of claim 29 to boost the immune response.
Dependencies are inferred from the claim text.